Envoy Medical to Present at the Emerging Growth Virtual Conference November 1

Investors interested in learning more encouraged to register for free at the Emerging Growth Conference website 

WHITE BEAR LAKE, Minnesota, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company, today announced that it will present to investors at the Emerging Growth virtual investor conference to be held November 1-2, 2023.

As part of the conference, Envoy Medical is scheduled to provide a group presentation at 10:15 a.m. ET on November 1, 2023, a webcast of which will be available in the Investor Relations section of the Company’s website at https://www.envoymedical.com.   

Registration for the webcast presentation is free and available on the Emerging Growth Conference website HERE. The presentation will include an opportunity for questions from the audience. Please submit your questions in advance to [e-mail] or ask your questions during the event.

To arrange a meeting with Envoy Medical, please contact Envoy Medical investor relations at [e-mail].  

About Envoy Medical

Envoy Medical, Inc. (NASDAQ: COCH), headquartered in White Bear Lake, Minnesota, is a hearing health company focused on providing innovative medical technologies.

Envoy Medical is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.

About the Fully Implanted Acclaim Cochlear Implant

Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. We believe the fully implanted Acclaim Cochlear Implant is a first-of-its-kind cochlear implant.

The Acclaim is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim is expected to be indicated only for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. We believe the Acclaim was the first hearing-focused device to receive Breakthrough Device Designation and may still be the only hearing focused medical technology to receive the designation.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by United States law to investigational use.

Important safety information for the Esteem can be found at: https://www.envoymedical.com/safety-information.